Lake Street Advisors Group LLC acquired a new position in Zimmer Biomet Holdings Inc (NYSE:ZBH) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 6,877 shares of the medical equipment provider’s stock, valued at approximately $830,000.
A number of other large investors have also recently made changes to their positions in ZBH. Wells Fargo & Company MN boosted its position in Zimmer Biomet by 98.8% during the 4th quarter. Wells Fargo & Company MN now owns 2,044,375 shares of the medical equipment provider’s stock valued at $246,695,000 after acquiring an additional 1,016,085 shares in the last quarter. Alyeska Investment Group L.P. boosted its position in Zimmer Biomet by 249.3% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,019,872 shares of the medical equipment provider’s stock valued at $119,417,000 after acquiring an additional 727,925 shares in the last quarter. Jana Partners LLC boosted its position in Zimmer Biomet by 16.6% during the 3rd quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock valued at $545,932,000 after acquiring an additional 662,497 shares in the last quarter. Two Sigma Advisers LP boosted its position in Zimmer Biomet by 823.1% during the 4th quarter. Two Sigma Advisers LP now owns 739,522 shares of the medical equipment provider’s stock valued at $89,238,000 after acquiring an additional 659,412 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in Zimmer Biomet by 14.7% during the 4th quarter. American Century Companies Inc. now owns 4,777,397 shares of the medical equipment provider’s stock valued at $576,488,000 after acquiring an additional 612,044 shares in the last quarter. 86.49% of the stock is currently owned by institutional investors.
Several analysts have issued reports on ZBH shares. Morgan Stanley dropped their target price on Zimmer Biomet from $150.00 to $148.00 and set an “overweight” rating on the stock in a research report on Monday, February 26th. Citigroup dropped their target price on Zimmer Biomet from $132.00 to $121.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 27th. Needham & Company LLC increased their target price on Zimmer Biomet from $144.00 to $155.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 30th. Oppenheimer initiated coverage on Zimmer Biomet in a report on Thursday, March 15th. They set an “outperform” rating and a $135.00 price objective for the company. Finally, BMO Capital Markets reiterated a “buy” rating and set a $142.00 price objective on shares of Zimmer Biomet in a report on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $140.63.
Zimmer Biomet Holdings Inc (ZBH) opened at $114.75 on Tuesday. The stock has a market capitalization of $23,733.65, a price-to-earnings ratio of 14.55, a P/E/G ratio of 2.03 and a beta of 1.13. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.50 and a quick ratio of 0.81. Zimmer Biomet Holdings Inc has a 52 week low of $108.03 and a 52 week high of $133.49.
Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $2.10. The company had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.03 billion. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the business posted $2.14 EPS. analysts forecast that Zimmer Biomet Holdings Inc will post 7.8 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.84%. Zimmer Biomet’s dividend payout ratio (DPR) is 10.65%.
TRADEMARK VIOLATION WARNING: This news story was published by Week Herald and is owned by of Week Herald. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://weekherald.com/2018/03/20/lake-street-advisors-group-llc-acquires-new-position-in-zimmer-biomet-holdings-inc-zbh.html.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.